Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C23H23NO3
CAS Number:
Molecular Weight:
361.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1
SMILES string
OC(=O)[C@H](C1CCCC1)c2ccc(OCc3ccc4ccccc4n3)cc2
InChI key
ZEYYDOLCHFETHQ-JOCHJYFZSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL (clear solution)
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Bay-X-1005 is a potent inhibitor of 5-lipoxygenase activating protein (FLAP).
Bay-X-1005 is a potent inhibitor of 5-lipoxygenase activating protein (FLAP). Bay-X-1005 inhibits A23187-induced LTB4 production in human leucocytes with an IC50 value of 220 nM, and blocks IgE mediated airway contractions.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Stefano Fiorucci et al.
British journal of pharmacology, 139(7), 1351-1359 (2003-08-02)
(1) Unlike other nonsteroidal anti-inflammatory drugs that inhibit formation of cyclooxygenase (COX)-dependent eicosanoids, acetylation of COX-2 by aspirin switches eicosanoid biosynthesis from prostaglandin E(2) (PGE(2)) to 15-epi-lipoxin A(4) (15-epi-LXA(4) or aspirin-triggered lipoxin, ATL). ATL formation by activated leukocytes (PMN) requires
Esther Titos et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 17(12), 1745-1747 (2003-09-06)
The existence of an increased number of Kupffer cells is recognized as critical in the initiation of the inflammatory cascade leading to liver fibrosis. Because 5-lipoxygenase (5-LO) is a key regulator of cell growth and survival, in the current investigation
P Roger et al.
Mediators of inflammation, 10(1), 33-36 (2001-04-28)
Increased secretion of mucus is a hallmark of many respiratory diseases and contributes significantly to the airflow limitation experienced by many patients. While the current pharmacological approach to reducing mucus and sputum production in patients is limited, clinical studies have
R Müller-Peddinghaus
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 48(4), 529-536 (1998-01-28)
Leukotrienes have been identified in various pathophysiologies. The leukotrienes LTB4 and LTC4 are assigned to inflammation. 5-lipoxygenase inhibitors which inhibit the synthesis of LTA4 being the precursor of both LTB4 and LTC4 appear to have only a limited antiinflammatory potential.
A R Fischer et al.
Thorax, 52(12), 1074-1077 (1998-03-28)
Leukotrienes have been implicated in the mediation of airway obstruction induced by hyperventilation of cold dry air in asthmatic subjects. The effect of a novel inhibitor of 5-lipoxygenase activating protein, BAYx 1005, on the bronchospastic response to cold dry air
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service